Developing a Quality Measure for Clinical Inertia in Diabetes Care

Abstract

Objective. To develop a valid quality measure that captures clinical inertia, the failure to initiate or intensify therapy in response to medical need, in diabetes care and to link this process measure with outcomes of glycemic control. Data Sources. Existing databases from 13 Department of Veterans Affairs hospitals between 1997 and 1999. Study Design. Laboratory results, medications, and diagnoses were collected on 23,291 patients with diabetes. We modeled the decision to increase antiglycemic medications at individual visits. We then aggregated all visits for individual patients and calculated a treatment intensity score by comparing the observed number of increases to that expected based on our model. The association between treatment intensity and two measures of glycemic control, change in HbA1c during the observation period, and whether the outcome glycosylated hemoglobin (HbA1c) was greater than 8 percent, was then examined. Principal Findings. Increases in antiglycemic medications occured at only 9.8 percent of visits despite 39 percent of patients having an initial HbA1c level greater than 8 percent. A clinically credible model predicting increase in therapy was developed with the principal predictor being a recent HbA1c greater than 8 percent. There were considerable differences in the intensity of therapy received by patients. Those patients receiving more intensive therapy had greater improvements in control ( po.001).Conclusions. Clinical inertia can be measured in diabetes care and this process measure is linked to patient outcomes of glycemic control. This measure may be useful in efforts to improve clinicians management of patients with diabetes.Key Words. Diabetes mellitus, outcomes assessment, quality of health careCentral to improving clinical practice is reliable and valid measures of the quality of care. While process and outcome measures each play an important role in quality measurement, it has long been recognized that the development of process measures that are linked to outcomes is an important r Health Research and Educational Trust

Missed Opportunities in Diabetes Management: A Longitudinal Assessment of Factors Associated with Sub-optimal Quality

“…20,27,30 Berlowitz et al found that intensification of therapy was related to better blood pressure control 27 and that intensification of diabetes medications improved glycemic control over 2 years. 30 Additionally, Brown et al's study 20 found a peak in glycemic excursion prior to the addition of the metformin and that patients spent numerous months above target A1c before a therapeutic change was made. Straka et al 31 found that 70% of subjects who were above the LDL target of 100 mg/dl were not on lipid medications.…”

Perceptions of Usability and Design for Prefilled Insulin Delivery Devices for Patients With Type 2 Diabetes

“…5 The inappropriate intensification of treatment to insulin therapy further affects glycemic control, has a direct impact on patient encounters, and may affect adherence to medications. [6][7][8][9][10] Earlier use of insulin in patients with type 2 diabetes has therefore been recommended by the European Association for the Study of Diabetes and the American Diabetes Association. 3 Delays in initiating insulin therapy may result from patients' psychological resistance to insulin, clinical inertia, or a combination thereof.…”

Therapeutic inertia in the management of hyperlipidaemia in type 2 diabetic patients: a cross-sectional study in the primary care setting

“…This threshold effect has been commonly observed in other similar studies. 30,35 Other factors that contribute to the threshold effect could be 'overestimation of current care' or 'complacency with borderline values' , leading to the physician's subjective misperception that the care provided is sufficient. 34 …”